Royal Bank of Canada
AXDX

Royal Bank of Canada’s Accelerate Diagnostics AXDX Stock Holding History

Royal Bank of Canada’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,240
Closed -$210K – 6656
2019
Q4 		$210K Buy
+1,240
New +$205K ﹤0.01% 4607

Other funds holding AXDX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Cannell & Spears New York $5.62B AUM 41.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada's AXDX Position: Q1 2025 in Review

Royal Bank of Canada sold out of Accelerate Diagnostics (AXDX) in Q1 2025, closing a stake of 4,776 shares — an estimated $6K sold.

Royal Bank of Canada first reported a position in AXDX in Q3 2013 and held it in 43 quarters. The position peaked at $3.05M in Q2 2020. 43 funds tracked by Wall St. Rank hold AXDX as of Q1 2025.

  • Royal Bank of Canada reported no remaining Accelerate Diagnostics position as of Q1 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 4,776 Accelerate Diagnostics shares in Q1 2025, an estimated $6K.
  • Royal Bank of Canada first reported a position in Accelerate Diagnostics in Q3 2013 and held it in 43 quarters.
  • Royal Bank of Canada's Accelerate Diagnostics position peaked at $3.05M in Q2 2020.
  • 43 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2025.

Based on Royal Bank of Canada's 13F filing for Q1 2025, filed 15 May 2025.